These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 22772530)
1. Accord could make Canadian generics industry a 'rust bucket'. Hoag H Nat Med; 2012 Jul; 18(7):991. PubMed ID: 22772530 [No Abstract] [Full Text] [Related]
3. Generics vs. patent drugs: a very Canadian debate, eh? Page B Can Oncol Nurs J; 1998 Feb; 8(1):2. PubMed ID: 9677919 [No Abstract] [Full Text] [Related]
4. The importance of being first: evidence from Canadian generic pharmaceuticals. Hollis A Health Econ; 2002 Dec; 11(8):723-34. PubMed ID: 12457372 [TBL] [Abstract][Full Text] [Related]
5. Indian biogenerics industry emerges. Jayaraman KS Nat Biotechnol; 2003 Oct; 21(10):1115-6. PubMed ID: 14520378 [No Abstract] [Full Text] [Related]
6. Competition and the Reference Pricing Scheme for pharmaceuticals. Ghislandi S J Health Econ; 2011 Dec; 30(6):1137-49. PubMed ID: 21937137 [TBL] [Abstract][Full Text] [Related]
7. Monitoring the price of new drugs. Silversides A CMAJ; 2006 May; 174(11):1548-9. PubMed ID: 16717260 [No Abstract] [Full Text] [Related]
8. Folly or volley? Will a dollar $4 pill finally open the healthcare market to competitive pricing? Sturm AC Healthc Financ Manage; 2006 Nov; 60(11):120-2. PubMed ID: 17094287 [No Abstract] [Full Text] [Related]
9. Trade agreements and health in developing countries. Stiglitz JE Lancet; 2009 Jan; 373(9661):363-5. PubMed ID: 19167055 [No Abstract] [Full Text] [Related]
10. Generics industry and doctors nervous over free trade deal. Burton B BMJ; 2004 May; 328(7449):1158. PubMed ID: 15142916 [No Abstract] [Full Text] [Related]
11. Price regulation and generic competition in the pharmaceutical market. Dalen DM; Strøm S; Haabeth T Eur J Health Econ; 2006 Sep; 7(3):208-14. PubMed ID: 16841230 [TBL] [Abstract][Full Text] [Related]
12. The impact of generic substitution on price competition in Finland. Aalto-Setälä V Eur J Health Econ; 2008 May; 9(2):185-91. PubMed ID: 17508226 [TBL] [Abstract][Full Text] [Related]
13. [Free trade agreements make the drugs more expensive]. Jeppsson A Lakartidningen; 2009 Nov 18-24; 106(47):3181. PubMed ID: 20082499 [No Abstract] [Full Text] [Related]
14. [Parallel import of drugs]. Rygnestad T; Fredriksen G; Spigset O Tidsskr Nor Laegeforen; 1999 Apr; 119(11):1573. PubMed ID: 10385794 [No Abstract] [Full Text] [Related]
15. US trade rep is pressing Indian government to forbid production of generic cancer drug, consortium says. Cohen D BMJ; 2014 Nov; 349():g6593. PubMed ID: 25370846 [No Abstract] [Full Text] [Related]
16. The Problem of Limited-Supply Agreements for Medicare Price Negotiation. Gabriele SME; Feldman WB JAMA; 2023 Oct; 330(13):1223-1224. PubMed ID: 37713185 [TBL] [Abstract][Full Text] [Related]
17. A few specialty drug prices fall--all generics. Manag Care; 2008 Dec; 17(12):46. PubMed ID: 19127766 [No Abstract] [Full Text] [Related]
18. Indian generics companies go on spending spree. Jayaraman KS Nat Rev Drug Discov; 2005 Aug; 4(8):616-7. PubMed ID: 16106583 [No Abstract] [Full Text] [Related]
19. Drug marketing exclusivity under United States and European Union law. Junod V Food Drug Law J; 2004; 59(4):479-518. PubMed ID: 15875347 [No Abstract] [Full Text] [Related]
20. Path to approval proves rocky for copycat biodrugs. Wadman M Nature; 2005 Nov; 438(7065):154-5. PubMed ID: 16281004 [No Abstract] [Full Text] [Related] [Next] [New Search]